1. Home
  2. AMCR vs RPRX Comparison

AMCR vs RPRX Comparison

Compare AMCR & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Amcor plc

AMCR

Amcor plc

HOLD

Current Price

$8.25

Market Cap

19.0B

ML Signal

HOLD

Logo Royalty Pharma plc

RPRX

Royalty Pharma plc

HOLD

Current Price

$38.29

Market Cap

16.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMCR
RPRX
Founded
1926
1996
Country
Switzerland
United States
Employees
N/A
N/A
Industry
Miscellaneous manufacturing industries
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
19.0B
16.2B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
AMCR
RPRX
Price
$8.25
$38.29
Analyst Decision
Buy
Strong Buy
Analyst Count
7
4
Target Price
$10.40
$45.75
AVG Volume (30 Days)
21.1M
4.0M
Earning Date
11-05-2025
11-05-2025
Dividend Yield
6.32%
2.29%
EPS Growth
N/A
N/A
EPS
0.32
1.75
Revenue
$17,401,000,000.00
$2,349,844,000.00
Revenue This Year
$57.16
$37.13
Revenue Next Year
$1.28
$1.48
P/E Ratio
$25.68
$21.92
Revenue Growth
28.42
3.70
52 Week Low
$7.67
$24.05
52 Week High
$10.45
$41.24

Technical Indicators

Market Signals
Indicator
AMCR
RPRX
Relative Strength Index (RSI) 46.43 47.16
Support Level $8.31 $37.88
Resistance Level $8.59 $39.88
Average True Range (ATR) 0.13 0.91
MACD -0.03 -0.22
Stochastic Oscillator 28.57 35.27

Price Performance

Historical Comparison
AMCR
RPRX

About AMCR Amcor plc

Amcor is a global producer of plastic packaging primarily for the fast-moving consumer goods industry. About 90% of earnings are exposed to the flexible packaging business. This is soft disposable plastic for a variety of food, drink, healthcare, and hygiene products. The remainder of earnings are from the Latin and North American rigids business, which is primarily beverage bottling for the soft drink industry. Operating in more than 35 countries, Amcor has market share in its established regions of North America, Latin America, Europe, and Asia-Pacific. About half of group sales are derived from North America and the remainder is split equally between Western Europe and emerging markets. Australia and New Zealand sales make up less than 5% of group sales.

About RPRX Royalty Pharma plc

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Share on Social Networks: